摘要
近年来,非小细胞肺癌(non-small cell lung cancer,NSCLC)在手术治疗、放疗、化疗及靶向治疗方面均取得了很大的进展,但晚期NSCLC患者的5年生存率仍然很低。免疫治疗利用免疫系统来控制和清除瘤细胞,已成为肿瘤治疗的一种重要手段。NSCLC的免疫治疗近期取得了突破性的进展,抗原特异性肿瘤疫苗、检查点阻滞剂等多种新型抗肿瘤免疫治疗药物已进行NSCLC治疗的临床试验,并在II期和III期临床试验中取得一定的成果。目前已完善了免疫治疗疗效评估标准,成为免疫治疗药物抗肿瘤评价标准。免疫治疗将成为NSCLC治疗的一种重要手段。
In recent years, the five-year survival rate of patients with advanced stage non-small cell lung cancer （NSCLC） remains low despite recent advances in surgery, irradiation, chemotherap）5 and targeted therapy. Immunotherapy which utilizes the immune system to control and eradicate cancer is a viable treatment approach for malignancy. Immunother- apy in patients with lung cancer has made breakthrough progress recently. Novel immunotherapeutic agents, such as antigen- specific tumour vaccines, checkpoint inhibitors, etc, have all been evaluated in lung cancer, and some have shown prolonged survival time in phase II trials and III trails. The immune-related response criteria for the evaluation of antitumor responses with immunotherapeutic agents have been made. Now, immunotherapy will likely be a fundamentally new concept for the treatment of NSCLC.
出处
《中国肺癌杂志》
CAS
北大核心
2014年第1期34-41,共8页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
免疫治疗
肿瘤疫苗
调定点阻滞剂
Lung neoplasms
Immunotherapy
Tumour vaccines
Checkpoint inhibitors
